Similar articles

• Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment.

  Pisani F, Fazio A, Spina E, Artesi C, Pisani B, Russo M, Trio R, Perucca E. Pisani F, et al. Psychopharmacology (Berl). 1986;90(3):295-8. doi: 10.1007/BF00179180. Psychopharmacology (Berl). 1986. PMID: 3097715
• Pharmacokinetics of viloxazine hydrochloride in man.

  Vandel B, Vandel S, Jounet JM, Blum D. Vandel B, et al. Eur J Drug Metab Pharmacokinet. 1982 Jan-Mar;7(1):65-8. doi: 10.1007/BF03189545. Eur J Drug Metab Pharmacokinet. 1982. PMID: 7067726
• [Synopsis of psychopathological, electroencephalographical, and pharmacokinetic variables during antidepressive treatment with viloxazine (author's transl)].

  Busch H, Bente D, Müller-Oerlinghausen B, Renfordt E. Busch H, et al. Arzneimittelforschung. 1978;28(8):1288-90. Arzneimittelforschung. 1978. PMID: 380579 Clinical Trial. German.
• Viloxazine: a review of the literature.

  Ban TA, McEvoy JP, Wilson WH. Ban TA, et al. Int Pharmacopsychiatry. 1980;15(2):118-23. doi: 10.1159/000468422. Int Pharmacopsychiatry. 1980. PMID: 7002831 Review.
• Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

  Pinder RM, Brogden RN, Speight TM, Avery GS. Pinder RM, et al. Drugs. 1977 Jun;13(6):401-21. doi: 10.2165/00003495-197713060-00001. Drugs. 1977. PMID: 324751 Review. No abstract available.